YOLFTbeta
Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc

PHAT · NASDAQ · Healthcare / Biotechnology

6.06USD-0.17 (-2.73%)

Price History

Full chart

Market Stats

Previous Close6.23
Open6.24
Day Range5.78 – 6.24
52-Week Range6.91 – 18.31
Volume1.51M
Market Cap590.58M
P/E (TTM)0.00
Forward P/E6.60
EPS-1.27
Dividend Yield0.00%
Beta0.51
50-Day Avg9.19
200-Day Avg11.62

About

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Steven L. Basta M.B.A.
  • Employees371
  • Headquarters100 Campus Drive, Florham Park, NJ, United States, 07932, USA
  • Websitehttps://www.phathompharma.com

Leadership

  • Mr. Steven L. Basta M.B.A.CEO, President & Director · b. 1966
  • Mr. David A. SocksCo-Founder · b. 1975
  • Dr. Azmi Nabulsi M.D., M.P.H.Co-Founder · b. 1960
  • Mr. Sanjeev NarulaChief Financial & Business Officer · b. 1961
  • Ms. Anne Marie Cook Esq., J.D.Chief Legal Officer & Corporate Secretary · b. 1962
  • Mr. Jonathan BentleySenior VP and Head of Sales, Operations & Training
  • Mr. Robert BreedloveVP of Finance & Principal Accounting Officer
  • Mr. Eric SciorilliDirector of Business Development & Investor Relations
  • Mr. Bill Aprea J.D.Senior VP, Chief Compliance Officer & Deputy Chief Legal Officer
  • Ms. Nancy R. PhelanSenior Vice President of Marketing & Analytics · b. 1969

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000682.00K55.25M175.11M
Growth (%)------+8001.47%+216.93%
Cost of Revenue-8.00K300.00K521.00K620.00K167.00K7.97M22.60M
Gross Profit--8.00K-300.00K-521.00K-620.00K515.00K47.28M152.51M
Gross Margin-----75.51%85.57%87.09%
Operating Expense-106.21M125.36M134.56M171.82M167.83M324.75M312.50M
Operating Income-1.23M-106.22M-125.67M-135.08M-172.44M-167.31M-277.47M-159.99M
Operating Margin------24532.55%-502.18%-91.36%
EBITDA-50.00K-250.95M-124.19M-136.57M-169.80M-159.05M-261.52M-152.50M
EBITDA Margin------23320.97%-473.33%-87.09%
Net Income-1.29M-209.74M-129.07M-143.88M-197.72M-201.59M-334.33M-221.25M
Net Income Margin------29558.94%-605.09%-126.35%
R&D20.00K99.27M98.15M72.34M71.44M49.90M34.08M32.78M
R&D as % of Total Revenue-----7316.57%61.68%18.72%
Interest Expense13.00K4.18M4.58M6.79M27.30M41.97M72.01M68.11M
Interest Expense % of Total Revenue-----6153.67%130.33%38.90%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets902.00K257.18M295.11M189.43M164.81M413.84M378.32M259.15M
Total Liabilities2.19M29.22M100.84M117.28M239.62M486.60M631.90M697.32M
Total Equity-1.29M227.96M194.27M72.16M-74.81M-72.76M-253.58M-438.17M
Cash879.00K243.76M287.50M183.26M155.38M381.39M297.26M129.97M
Total Debt1.95M23.57M49.02M91.34M97.07M139.03M201.91M211.80M
Net Debt1.07M-220.19M-238.48M-91.92M-58.31M-242.36M-95.35M81.83M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.02M-36.51M-69.69M-148.46M-146.53M-137.58M-266.77M-166.78M
Investing Cash Flow-25.25M-25.25M-1.04M-328.00K-1.04M-1.63M-135.00K-229.00K
Financing Cash Flow1.90M304.65M114.46M44.71M120.04M367.58M182.77M-288.00K
Capital Expenditure132.00K25.25M1.04M328.00K1.04M1.63M135.00K229.00K
Free Cash Flow-1.02M-61.76M-70.73M-148.78M-147.57M-139.21M-266.90M-166.78M
FCF to OCF100.00%169.16%101.49%100.22%100.71%101.19%100.05%100.00%

Earnings

Report DateNov 25, 2019Mar 19, 2020May 12, 2020Aug 6, 2020Nov 10, 2020Mar 30, 2021May 11, 2021Aug 10, 2021Nov 8, 2021Mar 1, 2022May 10, 2022Aug 2, 2022Nov 8, 2022Feb 28, 2023May 10, 2023Aug 10, 2023Nov 9, 2023Mar 7, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 6, 2025May 7, 2025Aug 7, 2025Oct 30, 2025Feb 26, 2026May 12, 2026Jul 30, 2026Oct 29, 2026
EPS Estimate-3.02-1.25-0.72-0.62-0.67-1.12-1.19-0.99-1.03-1.03-1.02-1.11-1.33-1.35-1.28-0.95-0.96-1.08-1.22-1.24-1.46-1.08-1.07-0.86-0.41-0.20-0.39-0.15-0.01
EPS Actual-3.72-3.97-0.62-0.64-1.02-1.58-0.96-1.00-0.98-0.95-1.07-1.33-1.32-1.33-0.89-0.84-0.76-1.39-1.11-1.25-1.05-1.05-1.07-0.90-0.15-0.16-0.18-0.08-
Surprise-23.18%-217.60%13.89%-3.23%-52.24%-41.07%19.33%-1.01%4.85%7.77%-4.90%-19.82%0.75%1.48%30.47%11.58%20.83%-28.70%9.02%-0.81%28.08%2.78%-0.38%-4.65%63.41%20.00%53.81%46.67%-
TimingPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap590.58M
Enterprise Value550.13M
Trailing P/E0.00
Forward P/E6.60
Price / Sales2.46
Price / Book25.37
EPS-1.27
Book Value-4.30
Revenue (TTM)239.66M
Gross Profit (TTM)198.73M
EBITDA-40.13M
Profit Margin-41.34%
Operating Margin-5.34%
Return on Equity-3489.00%
Return on Assets-8.80%
Shares Outstanding80.90M
Shares Float65.29M
Beta0.51
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 9 analystsTarget 20.45
  • Strong Buy
    6
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
92.49%
Insiders
4.66%
Retail / Other
2.85%

Top Institutional Holders

  • Frazier Life Sciences Management, L.P.
    12.47M15.41%
  • Medicxi Ventures Management (Jersey) Ltd
    7.46M9.23%
  • Amvescap Plc.
    4.32M5.34%
  • BlackRock Inc
    4.06M5.02%
  • The Carlyle Group Inc
    3.50M4.32%
  • Millennium Management LLC
    3.38M4.17%
  • Vanguard Capital Management, LLC
    2.58M3.19%
  • NEA Management Company, LLC
    1.96M2.42%
  • 683 Capital Management LLC
    1.85M2.29%
  • Ensign Peak Advisors Inc
    1.63M2.01%
  • Catalys Pacific LLC
    1.49M1.85%
  • GW&K Investment Management, LLC
    1.42M1.76%
  • State Street Corp
    1.39M1.71%
  • Geode Capital Management, LLC
    1.33M1.64%
  • Wasatch Advisors LP
    1.31M1.62%
  • Delaware Management Holdings Inc
    1.21M1.49%

Top Fund Holders

  • Invesco Global A
    2.34M2.90%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.01M2.48%
  • Strategic Advisers U.S. Total Stock
    1.36M1.68%
  • iShares Russell 2000 ETF
    1.26M1.56%